Buy discount Ozempic here now click this link
Aug 22, 2025•32 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Summary
The unprecedented demand for weight loss drugs like Ozempic, coupled with a supply shortage, has disrupted the traditional pharmaceutical market. This episode highlights how individuals like Phil, who lost insurance coverage for his life-changing medication, are navigating a new, unregulated world of compounding pharmacies and telehealth companies offering cheaper alternatives. This parallel market, fueled by global sourcing of active ingredients, creates a 'Wild West' scenario, challenging big pharma's monopolies and raising significant questions about drug safety and regulation.Episode description
In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them.
Now, in most industries, if a product goes viral like this, it’s a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.
In theory, anyway.
But, what if that explosive demand backfired, opening the door to legal knock-offs? You’ve maybe seen them - copycats advertised as the same thing as Ozempic. So, what’s the difference? And just how legal are they? On today’s show - a drug that’s changing people's lives is also challenging the traditional way we buy and sell medicine.
This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money’s executive producer.
Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.
Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.
Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.
Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
Now, in most industries, if a product goes viral like this, it’s a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.
In theory, anyway.
But, what if that explosive demand backfired, opening the door to legal knock-offs? You’ve maybe seen them - copycats advertised as the same thing as Ozempic. So, what’s the difference? And just how legal are they? On today’s show - a drug that’s changing people's lives is also challenging the traditional way we buy and sell medicine.
This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money’s executive producer.
Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.
Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.
Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.
Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
For the best experience, listen in Metacast app for iOS or Android